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Abstract
Background: Endometrial cancer is one of the most common gynecologic malignancies and its
incidence has recently increased. Experimental and epidemiological data support that testosterone
plays an important role in the pathogenesis of endometrial cancer, but the underlying mechanism
has not been fully understood. Recently, we identified and cloned a variant of estrogen receptor
(ER) alpha, ER-alpha36. The aim of the present study was to investigate the role of ER-alpha36 in
testosterone carcinogenesis.
Methods: The cellular localization of ER-alpha36 was determined by immunofluorescence. Hec1A
endometrial cancer cells (Hec1A/V) and Hec1A cells with siRNA knockdown of ER-alpha36
(Hec1A/RNAi) were treated with testosterone, ERK and Akt phosphorylation was assessed by
Western blot analysis. Furthermore, the kinase inhibitors U0126 and LY294002 and the aromatase
inhibitor letrozole were used to elucidate the pathway underlying testosterone-induced activities.
Results: Immunofluorescence shows that ER-alpha36 was localized on the plasma membrane of
the both ER-alpha- and androgen receptor-negative endometrial cancer Hec1A cells. Testosterone
induced ERK and Akt phosphorylation, which could be abrogated by ER-alpha 36 shRNA
knockdown or the kinase inhibitors, U0126 and LY294002, and the aromatase inhibitor letrozole.
Conclusion: Testosterone induces ERK and Akt phosphorylation via the membrane-initiated
signaling pathways mediated by ER-alpha36, suggesting a possible involvement of ER-alpha 36 in
testosterone carcinogenesis.
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Background
Endometrial cancer represents one of the most common
female pelvic malignancies and is the fourth most com-
mon type of cancer in North American and European
women [1,2]. There are many risk factors for endometrial
cancer, such as polycystic ovarian syndrome (PCOS),
obesity, age at menopause, prolonged exposure to endog-
enous estrogens [3,4]. Recently, epidemiological studies
have found that testosterone is associated with increasing
endometrial cancer risk [5]. However, the molecular
mechanism underlying testosterone carcinogenesis has
not been established.
The Mitogen-activated protein kinase (MAPK) plays a key
role in regulating cell differentiation and proliferation
and provides protection against apoptosis [6]. MAPK is
the pivotal component of intracellular phosphorylation
cascades in both cytoplasm and the nucleus [7,8] and ele-
vated MAPK activity has been detected in invasive breast
carcinomas compared with the surrounding benign breast
tissue [9]. Akt, also known as protein kinase B, is a well-
characterized serine/threonine kinase that is activated by
a variety of stimuli, including epidermal growth factor,
insulin, heregulin, vascular endothelial growth factor or
steroids, in a phosphoinositide-3-OH kinase (PI3K)-
dependent manner [10-13]. Activated Akt promotes cell
proliferation and survival by phosphorylating and modu-
lating the activity of various transcription factors in the
nucleus. Genetic and biochemical evidence suggest that
aberrant activation of the PI3K/Akt pathway contributes
to tumorigenesis, which is associated with a worse out-
come [14]. The up-regulation of PI3K/Akt cascades is also
found in human endometrial cancer tissues [15].
Recently, we identified and cloned a novel variant of
estrogen receptor α with a molecular weight of 36 kDa
that is transcribed from previously unidentified promoter
located in the first intron of the original estrogen receptor
α (ER-α66) gene [16]. ER-α36 differs from ER-α66 by
lacking both transcriptional activation domains (AF-1
and AF-2), but it retains the DNA-binding domain and
partial ligand-binding domains. It possesses a unique 27
amino acid domain that replaces the last 138 amino acids
encoded by exons 7 and 8 of the ER-α66 gene. In the
present study, we studied the ER-α36 function in endome-
trial cancer Hec1A cells, and explored the contribution of
the MAPK/ERK and PI3K/Akt pathways mediated by ER-
α36 to testosterone carcinogenesis.
Methods
Materials and reagents
Anti-ERK1/2 antibody, anti-phospho-ERK1/2 antibody
(Thr202/Tyr204), anti-Akt antibody, anti-androgen receptor
antibody, anti-estrogen receptor α antibody and anti-β-
actin antibody were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Anti-phospho-Akt (Ser473) anti-
body was obtained from Cell Signaling Technology
(Beverly, MA). Anti-aromatase antibody was purchased
from Novus Biologicals (Novus Biologicals, Littleton,
CO). ER-α36 specific antibody against the 20 unique
amino acids at the C-terminal of ER-α36, was described
before [16,17]. U0126 was purchased from Calbiochem
(La Jolla, CA). LY294002, testosterone and estrogen were
obtained from Sigma (St. Louis, MO). Letrozole was
obtained from TRC (Toronto, Cananda).
Cell culture and cell lines
Human ER-positive breast cancer MCF-7 cells and human
prostate cancer LNCaP cells were obtained from American
Type Culture Collection (Manassas, VA). MCF-7 cells were
maintained at 37°C and 5% CO2 in DMEM (Gibcol-BRL,
USA) with 10% fetal calf serum (Hyclone, UT). LNCaP
cells were cultured in RPMI-1640 medium with 10% fetal
calf serum and maintained at 37°C in a humidified
atmosphere of 5% CO2. Human Hec1A endometrial can-
cer cells were provided by Dr. Li-Hui Wei (Peking Univer-
sity People's Hospital, Beijing). Hec1A cells were grown at
37°C with 5% CO2 in DMEM supplemented with 10%
fetal calf serum. To establish stable cell line with ER-α36
expression knocked down by shRNA from Hec1A cells, we
constructed an ER-α36 specific shRNA expression vector
by cloning the DNA oligonucleotides5'-GATGCCAAT
AGGTACTGAATTGATATCCGTTCAGTACCTATTGGCAT-
3' from the 3'UTR of ER-α36 cDNA into the pRNAT-U6.1/
Neo expression vector from GenScript Corp. We estab-
lished stable Hec1A cell lines transfected with an ER-α36
shRNA expression vector (Hec1A/RNAi) and the empty
expression vector (Hec1A/V). Briefly, the ER-α36 shRNA
expression vector pRNAT-U6.1/Neo plasmid containing
the shRNA against ER-α36 and the empty expression vec-
tor were transfected into Hec1A cells with Lipofectamine
2000 (Invitrogen, Carlsbad, CA) according to the manu-
facturer's instruction as described elsewhere [17]. Forty-
eight hours after transfection, cells were re-plated and
selected with 600 μg/ml of G418 for two weeks. The
medium was changed every three days until colonies
appeared. Clones were pooled and expanded for further
analysis. Hec1A/RNAi cell line is a mixture of more then
twenty clones. A cell line with pooled clones transfected
with the empty expression vector was termed Hec1A/V
and used as a control.
Immunofluorescence and confocal microscopy
The cellular localization of ER-α36 was determined by
indirect immunofluorescence. Hec1A cells cultured on
sterile glass coverslips were fixed in 4% paraformaldehyde
in PBS for 10 min. After being permeabilized with 0.4%
Triton X-100 for 10 min at room temperature, cells were
blocked in 4% BSA-supplemented PBS for 1 hour and
incubated overnight at 4°C with anti-ER-α36-specificReproductive Biology and Endocrinology 2009, 7:102 http://www.rbej.com/content/7/1/102
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antibody against the 20 unique amino acids at the C-ter-
minal of ER-α36. After three washes in PBS, the cells were
labeled with FITC-conjugated secondary antibody. The
DNA dye Hoechst 33258 was used for nuclear staining.
Microscopic analyses were performed using a Confocal
Laser-Scanning Microscope (Zeiss LSM 510 META, Ger-
many).
Western blotting analysis
Cells were grown in phenol-red-free DMEM (Gibcol-BRL,
USA) with 2.5% dextran charcoal-stripped fetal calf serum
(Biochrom AG, Germany) for 48-72 hours and then
switched to medium without serum 12 h before stimula-
tion by the agents indicated. The cells were collected in
ice-cold PBS, and the cell extracts were prepared in RIPA
buffer with proteinase inhibitor cocktail from Sigma (St.
Louis, MO). The protein concentrations of the cell lysates
were determined and boiled with gel-loading buffer for 5
min at 100°C. Immunoblotting was performed as desci-
bed previously [18]. Briefly, the proteins were separated
by 10% SDS-PAGE and then transferred to polyvinylidene
fluoride membranes. Following transfer, the membrane
were blocked in TBST (TBS containing 0.1% Tween 20)
containing 5% skimmed milk for 2 h, followed by incuba-
tion overnight at 4°C with appropriate primary antibod-
ies. After washing three times in TBST, 10 min each, the
membranes were incubated for 1 h at 37°C with 1:2000
horseradish peroxidase-conjugated appropriate secondary
antibodies. Finally, the membranes were processed and
visualized using the enhanced chemiluminescence detec-
tion system (Amersham, Piscataway, NJ).
Results
ER-α36 is expressed on the plasma membrane in Hec1A 
cells
ER-α36 is a novel variant of ER-α66 generated by alterna-
tive promoter usage and alternative splicing [16]. To
examine ER-α36 localization in Hec1A cells, immunoflu-
orescencewas performed with anti-ER-α36 antibody
raised against the 20 amino acids at the C-terminal of ER-
α36 that are unique to ER-α36 [17]. Immunofluorescent
staining revealed that ER-α36 is expressed on the plasma
membrane of Hec1A cells (Figure 1A). It has been
reported that endometrial cancer Hec1A cells are an ER-
α66-negative cell line [19]. Consistent with this, Western
blot analysis fails to detect the expression of ER-α66 (Fig-
Subcellular localization of ER-α36 Figure 1
Subcellular localization of ER-α36. Hec1A cells were fixed and immunofluorescently stained with the anti-ER-α36 specific 
antibody against the 20 unique amino acids at the C-terminal of ER-α36 (green). The cells were counterstained with Hoechst 
33258 (blue) to show the cell nuclei (A). Total protein was extracted from MCF-7, Hec1A and LNCaP cells and expression of 
ER-α66 (B) and androgen receptor (AR) (C) was analyzed by Western blot.Reproductive Biology and Endocrinology 2009, 7:102 http://www.rbej.com/content/7/1/102
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ure 1B). Moreover, we found that Hec1A cells do not
express androgen receptor (AR) (Figure 1C). Therefore,
the endometrial cancer Hec1A cell line is an ER-α66-neg-
ative and AR-negative cell line.
ER-α36 mediates testosterone-stimulated ERK activation
MAPK/ERK signaling participates in the development and
progression of many types of cancers including endome-
trial cancer [20]. To determine ER-α36 is involved non-
genomic testosterone signaling in endometrial cancer
cells, we first examined the phosphorylation levels of ERK,
a serine-threonine kinase involved in cell proliferation
[21]. As shown in Figure 2A, testosterone treatment
induced phosphorylation of ERK1/2 in Hec1A cells. Re-
probing the membrane with a total ERK1/2 antibody indi-
cated that the total ERK1/2 content was not changed. We
next examined the changes in ERK1/2 phosphorylation
after treatment with different doses of testosterone. As
shown in Figure 2B, testosterone induced a dose-depend-
ent increase in ERK1/2 phosphorylation.
To test the involvement of ER-α36 in testosterone activity
observed in Hec1A cells that lack ER-α66 and AR expres-
sion, we decided to knockdown ER-α36 expression with
the siRNA approach. We established a stable cell line that
expresses siRNA specifically against ER-α36 (Hec1A/
RNAi) and found that ER-α36 expression was down-regu-
lated in this cell line (Figure 2C). As shown in Figure 2D,
testosterone failed to induce ERK1/2 phosphorylation in
Hec1A/RNAi cells.
Extracellular regulated kinase kinase (MEK) acts upstream
of ERK1/2 to phosphorylate and activate ERK1/2 [22]. The
MEK specific inhibitor U0126 effectively inhibited the
ERK1/2 activation stimulated by testosterone (Figure 2E).
Our results indicated that the ER-α36-mediated Ras/MEK/
ERK pathway is involved in testosterone signaling.
ER-α36 mediates testosterone-stimulated Akt activation
The serine/threonine kinase Akt, or protein kinase B, plays
an important role in cell proliferation and survival [23].
We then tested whether testosterone treatment induces
Akt activation in Hec1A cells. As shown in Figure 3A, tes-
tosterone treatment induced the rapid phosphorylation of
Akt. Furthermore, testosterone induced dose-dependent
increase in Akt phosphorylation (Figure 3B). ER-α36
knockdown was able to abrogate testosterone-induced
Akt phosphorylation, indicating the involvement of ER-
α36 (Figure 3C). Pretreatment of Hec1A cells with the
PI3K inhibitor LY294002 effectively inhibited Akt activa-
tion stimulated by testosterone (Figure 3D), indicating
that testosterone regulates Akt phosphorylation through
PI3K. Thus, our data indicated that ER-α36 is involved in
testosterone-induced Akt activation.
ER-α36 mediates testosterone-stimulated ERK activation Figure 2
ER-α36 mediates testosterone-stimulated ERK acti-
vation. Time-course analysis of ERK1/2 phosphorylation in 
Hec1A cells treated with 10 nM testosterone (Test) for the 
indicated time points. The blot was stripped and re-probed 
with an anti-ERK1/2 antibody (A). Hec1A cells were treated 
5 min with different concentrations of testosterone, and then 
lysates were immunoblotted with a phospho-specific anti-
body of ERK1/2. The same blot was stripped and probed 
with an anti-ERK1/2 antibody (B). (C), Western blot analysis 
of ER-α36 expression in Hec1A/V and Hec1A/RNAi cells. 
Western blot analysis of phospho-ERK1/2 in Hec1A/V and 
Hec1A/RNAi ER-α36 cells treated with 10 nM testosterone 
for 5 min. The same blot was stripped and probed with an 
anti-ERK1/2 antibody (D). Lysates were prepared from 
Hec1A cells treated with vehicle (DMSO) (Lanes 1), 10 nM 
testosterone (Lanes 2 and 4) or pre-treated with 10 μM 
U0126 (Lanes 3 and 4) for 30 min and immunoblotted with 
antibodies against phospho-ERK1/2 or total ERK1/2 (E).Reproductive Biology and Endocrinology 2009, 7:102 http://www.rbej.com/content/7/1/102
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ER-α36 mediates testosterone-stimulated Akt activation Figure 3
ER-α36 mediates testosterone-stimulated Akt activa-
tion. Western blot analysis of phospho-Akt in Hec1A cells 
treated with 10 nM testosterone (Test) for the indicated 
time points. The same blot was stripped and probed with an 
anti-total Akt antibody (A). Hec1A cells were treated 5 min 
with different concentrations of testosterone, and cell lysates 
were immunoblotted with a specific antibody against phos-
pho-Akt. The same blot was stripped and probed with an 
anti-total Akt antibody (B). Western blot analyzed phospho-
Akt in Hec1A/V and Hec1A/RNAi ER36 cells treated with 10 
nM testosterone for 5 min. The same blot was stripped and 
probed with an anti-Akt antibody (C). Lysates were prepared 
from Hec1A cells treated with vehicle (DMSO) (Lanes 1), 10 
nM testosterone (Lanes 2 and 4) or pre-treated with 50 μM 
PI3K inhibitor LY294002 (Lanes 3 and 4) for 1 h and immu-
noblotted with antibodies against phospho-Akt or total Akt 
(D).
Letrozole inhibits ER-α36-mediated ERK and Akt phosphor- ylation Figure 4
Letrozole inhibits ER-α36-mediated ERK and Akt 
phosphorylation. Hec1A cells were pre-treated with 10 
nM aromatase inhibitor letrozole (Lanes 3 and 4) for 1 h and 
then the cells were treated with vehicle (DMSO) (Lanes 1) 
and 10 nM testosterone (Lanes 2 and 4) for 5 min. Phospho-
ERK1/2 (A) or phospho-Akt (B) were examined with specific 
antibodies. The same blot was stripped and probed with anti-
total ERK or Akt antibodies. Hec1A cells were treated with 
10 nM testosterone (Lanes 2) or together with 10 nM aro-
matase inhibitor letrozole (Lanes 3) overnight, and then aro-
matase expression was detected by Western blot using 
specific antibody against aromatase (C).
i4Reproductive Biology and Endocrinology 2009, 7:102 http://www.rbej.com/content/7/1/102
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Letrozole inhibits ER-α36-mediated ERK and Akt 
phosphorylation
Androgens are well-known to exert estrogenic effects via
their aromatization to estrogens. Accumulating evidence
suggest that estrogens are generated by in situ aromatiza-
tion from cells of pathologically altered endometrium in
postmenopausal women, which promotes malignant
growth of these cells. Previous study also demonstrated
that aromatase activity in the endometrium plays a vital
role in the malignant transformation of endometrial cells
by converting androgen into mitogenic estrogen in the
endometrial tissue [24]. To determine the role of aro-
matase in non-genomic signaling pathway mediated by
testosterone, we examined testosterone stimulated ERK
and Akt phosphorylation in Hec1A cells pre-treated by
letrozole, an aromatase inhibitor. As expected, letrozole
abrogated the phosphorylation of ERK and Akt stimulated
by testosterone (Figure 4A and 4B). In addition, we also
found that letrozole treatment reduced expression levels
of aromatase in Hec1A cells (Figure 4C). These data
strongly suggest that aromatase is involved in testosterone
activities in cells express ER-α36.
Discussion
Estrogen receptor is a member of the nuclear receptor
superfamily and function as ligand-dependent transcrip-
tion factor in the nucleus to mediate estrogen signaling.
However, accumulating evidence demonstrate that there
is a rapid (within seconds or minutes) estrogen signaling
which cannot be explained by genomic signaling pathway
that usually takes hours to function [25,26]. Recently, we
found that ER-α36 was expressed in ER-positive and ER-
negative breast cancer cells [27], suggesting that ER-α36
expression is regulated differently from ER-α66. In the
present study, we found that ER-α36 is expressed mainly
on the plasma membrane in ER-α66-negative endome-
trial cancer Hec1A cells and ER-α36 mediates membrane-
initiated MAPK/ERK and PI3K/Akt pathways induced by
testosterone.
It has been reported that endometrial cancer risk is
increased in both pre- and postmenopausal women with
elevated plasma levels of testosterone [5,28]. Early in the
neoplastic process, abnormal endometrial cells can
locally produce estrogens from the plasma pool of andro-
gen, and thus gain a growth advantage independent of cir-
culating estrogens [29,30]. The local concentration of
estrogens in endometrial cancer was reported to be higher
than that in the blood and the endometrium of cancer-
free women [31]. Indeed, previous studies have shown
that aromatase activity is increased in endometrial cancer
cells, but not normal endometrial cells [32]. Moreover,
elevated circulating androgen has also been associated
with hyperplasia of the endometrium, which generally
precedes and accompanies the occurrence of type I
endometrial carcinomas [33]. Aromatase is a key enzyme
in the synthesis of estrogen that is responsible for binding
of testosterone and catalyzes the series of reactions even-
tually resulting in estrogen production [34]. Previous
reports demonstrated that aromatase is present in
endometrial cancer tissue, suggesting that aromatase plays
a role in converting testosterone into mitogenic estrogens
in endometrial tissue [24,35]. Recently, a significant cor-
relation has been found between aromatase immunoreac-
tivity and poor prognosis in patients with endometrial
carcinoma [36]. This positive linkage indicates that local
aromatase contributes to tumor progression through the
in situ formation of estrogens. Here, we show that testo-
sterone stimulates the activation of both ERK1/2 and the
Akt signaling pathways in endometrial cancer Hec1A cells
that lack expression of ER-α66 and AR. Therefore, it is pos-
sible that the estrogen produced localy from testosterone
in endometrial cells could bind ER-α36 and then activate
MAPK/ERK and PI3K/Akt pathways.
PCOS is one of the most common endocrinopathies in
humans, which affects about 10% of women of reproduc-
tive age [37]. PCOS is characterized by the production of
endogenous progesterone and absence of ovulations and
an increased secretion of ovarian androgen [38]. The asso-
ciation between PCOS and endometrial carcinoma has
been reported for many years. The risk of development
from PCOS to endometrial cancer was examined in 1270
women with chronic anovulation. This study identified
the excess risk of endometrial cancer to be 3.1 [95% CI,
1.1-7.3] [33,39]. PCOS is a key risk factor especially for
endometrial cancer among young, premenopausal
women [40]. It is possible that increased rate by which
androgen is converted to estrogen via aromatization,
which then stimulates both the MAPK/ERK and the PI3K/
Akt signaling pathways through ER-α36. The activation of
ERK and Akt is involved the development of endometrial
cancer [15,41].
Epidemiological, experimental and clinical result have
shown that estrogen plays a key role in the development
and progression of endometrial cancer [1]. Aromatase
inhibitor inhibits local estrogen production in postmeno-
pausal women and is used to treat postmenopausal
women with breast cancer [42]. The large trials demon-
strated that aromatase inhibitor contributed to improved
disease-free survival and good tolerability in breast cancer
patients [43]. Recently, aromatase inhibitor has been
shown to reduce proliferation and increase apoptosis in
endometrial cancer in vitro [44,45]. Letrozole is a compet-
itive nonsteroidal aromatase inhibitor that suppresses
over 85% of circulating levels of estrogen and over 98% of
aromatization in postmenopausal patients with breast
cancer [46]. In our study, we found that letrozole abro-
gated testosterone-induced ERK and Akt phosphorylation,Reproductive Biology and Endocrinology 2009, 7:102 http://www.rbej.com/content/7/1/102
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suggesting that aromatase might be involved in testoster-
one carcinogenesis.
Conclusion
In summary, we have shown that a novel variant of ER-
α66, ER-α36 is localized on the plasma membrane of
endometrial cancer Hec1A cells. We demonstrated that
testosterone induces ERK and Akt phosphorylation via
ER-α36-mediated membrane-initiated pathways. The
present study thus shed new light on understanding testo-
sterone-stimulated endometrial carcinogenesis. Further
research of ER-α36 functions may provide novel informa-
tion for designing new drugs for the treatment of endome-
trial cancer.
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